Novel molecule created in Cuba receives patent in New Zealand

Havana, Jun 22 (Prensa Latina) JM-20, a molecule developed by Cuba’s Center for Research and Development of Medicines (CIDEM), was patented in New Zealand to be used to treat Parkinson’s disease.

The Biotechnological and Pharmaceutical Industries Group, BioCubaFarma, informed on its Facebook profile that JM-20 can also be used for neuropathic pain and different kinds of dementia, such as Alzheimer’s disease and vascular dementia.

This molecule was developed in conjunction the Faculty of Chemistry at the University of Havana to treat cerebral ischemia. As preclinical studies progressed, it showed potential to treat other neurodegenerative diseases.

JM-20, as a hybrid molecule, influences different therapeutic targets related to neuroprotection, a quality that confirms the validity and novelty of a product such as this one.

The molecule has been patented in more than 25 international territories, including the leading global pharmaceutical markets in the United States, Europe, Japan, China, Eurasian nations, Brazil, Korea, and Canada.

jg/iff/jha/crc

This entry was posted in Healthcare. Bookmark the permalink.